Since the recent past, sodium-glucose cotransporter type 2 inhibitors (SGLT2i) have
been recommended as mainstay therapy for patients with chronic heart failure (HF)
and reduced ejection fraction (HFrEF) due to their positive effects on mortality,
clinical events, and quality of life. (
[1]
) Thus, clinical practice guidelines have recommended its use regardless of a history
of diabetes. (
[2]
) On the other hand, the appropriateness of its introduction during the acute phase
of HF is less well defined. There seems to be increasing evidence from clinical trial
sub-analyses that these drugs can produce early benefits, with clinically significant
reductions in clinical events within days or weeks after hospital discharge. (
[3]
) However, these data have not been verified in real life as the use of these drugs
has not been fully implemented in the cardiac decompensation phase. This study aimed
to compare in a real-world setting whether, in patients hospitalized for decompensated
HF, the prescription of an SGLT2i versus no prescription during admission results
in lower short-term morbidity and mortality.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.Lancet [Internet]. 2021; 398 (Available from: http://dx.doi.org/10.1016/S0140-6736(21)00536-5): 262-276
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.Eur Heart J. 2021; : 1-128
- Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).Eur J Heart Fail. 2020; 22: 713-722
- Dapagliflozin in patients with heart failure and reduced ejection fraction.N Engl J Med. 2015; : 687-696
- Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: deliver trial.JACC Heart Fail. 2022; 10: 184-197
- Sotagliflozin in patients with diabetes and recent worsening heart failure.N Engl J Med. 2021; 384: 117-128
- The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.Nat Med. 2022; 28: 2-4
- Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.Cardiovasc Diabetol [Internet]. 2022; 21 (Available from:): 20https://doi.org/10.1186/s12933-022-01455-2
- Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review.JACC Basic to Transl Sci. 2020; 5: 632-644
- SGLT2 (Sodium-Glucose Cotransporter-2) inhibitor–mediated blunting of blood volume redistribution: a candidate mechanism for attenuating cardiac filling pressures and exercise intolerance in heart failure—how do the data stack up?.Circ Hear Fail. 2022; 15: 208-210
Article info
Publication history
Published online: June 27, 2022
Accepted:
June 9,
2022
Received:
May 30,
2022
Identification
Copyright
© 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
